Transmembrane stem factor nanodiscs enhanced revascularization in a hind limb ischemia model in diabetic, hyperlipidemic rabbits.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 Jan 2024
29 Jan 2024
Historique:
received:
29
05
2023
accepted:
24
01
2024
medline:
30
1
2024
pubmed:
30
1
2024
entrez:
29
1
2024
Statut:
epublish
Résumé
Therapies to revascularize ischemic tissue have long been a goal for the treatment of vascular disease and other disorders. Therapies using stem cell factor (SCF), also known as a c-Kit ligand, had great promise for treating ischemia for myocardial infarct and stroke, however clinical development for SCF was stopped due to toxic side effects including mast cell activation in patients. We recently developed a novel therapy using a transmembrane form of SCF (tmSCF) delivered in lipid nanodiscs. In previous studies, we demonstrated tmSCF nanodiscs were able to induce revascularization of ischemia limbs in mice and did not activate mast cells. To advance this therapeutic towards clinical application, we tested this therapy in an advanced model of hindlimb ischemia in rabbits with hyperlipidemia and diabetes. This model has therapeutic resistance to angiogenic therapies and maintains long term deficits in recovery from ischemic injury. We treated rabbits with local treatment with tmSCF nanodiscs or control solution delivered locally from an alginate gel delivered into the ischemic limb of the rabbits. After eight weeks, we found significantly higher vascularity in the tmSCF nanodisc-treated group in comparison to alginate treated control as quantified through angiography. Histological analysis also showed a significantly higher number of small and large blood vessels in the ischemic muscles of the tmSCF nanodisc treated group. Importantly, we did not observe inflammation or mast cell activation in the rabbits. Overall, this study supports the therapeutic potential of tmSCF nanodiscs for treating peripheral ischemia.
Identifiants
pubmed: 38287067
doi: 10.1038/s41598-024-52888-6
pii: 10.1038/s41598-024-52888-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2352Subventions
Organisme : NIH HHS
ID : 1R01HL141761-01
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Liang, J. et al. The C-kit receptor-mediated signal transduction and tumor-related diseases. Int. J. Biol. Sci. 9, 435–443. https://doi.org/10.7150/ijbs.6087 (2013).
doi: 10.7150/ijbs.6087
pubmed: 23678293
pmcid: 3654492
Futrega, K., King, M., Lott, W. B. & Doran, M. R. Treating the whole not the hole: necessary coupling of technologies for diabetic foot ulcer treatment. Trends Mol. Med. 20, 137–142. https://doi.org/10.1016/j.molmed.2013.12.004 (2014).
doi: 10.1016/j.molmed.2013.12.004
pubmed: 24485902
Rajendran, P. et al. The vascular endothelium and human diseases. Int. J. Biol. Sci. 9, 1057–1069. https://doi.org/10.7150/ijbs.7502 (2013).
doi: 10.7150/ijbs.7502
pubmed: 24250251
pmcid: 3831119
Avogaro, A., Albiero, M., Menegazzo, L., de Kreutzenberg, S. & Fadini, G. P. Endothelial dysfunction in diabetes. Role Reparat. Mech. 34, S285–S290. https://doi.org/10.2337/dc11-s239%JDiabetesCare (2011).
doi: 10.2337/dc11-s239%JDiabetesCare
Thiruvoipati, T., Kielhorn, C. E. & Armstrong, E. J. Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World J. Diabetes 6, 961–969. https://doi.org/10.4239/wjd.v6.i7.961 (2015).
doi: 10.4239/wjd.v6.i7.961
pubmed: 26185603
pmcid: 4499529
Tursi, F. J. & Walker, C. Essential keys to diagnosing and treating PAD in patients with diabetes. Podiatry Today 30, 12–17 (2017).
Na, C. R., Wang, S., Kirsner, R. & Federman, G. The elderly and peripheral arterial disease. Clin. Geriatrics. 19, 41–46 (2011).
Simons, M. & Ware, J. A. Therapeutic angiogenesis in cardiovascular disease. Nat. Rev. Drug Discov. 2, 863–871. https://doi.org/10.1038/nrd1226 (2003).
doi: 10.1038/nrd1226
pubmed: 14668807
Cooke, J. P. & Meng, S. Vascular regeneration in peripheral artery disease. Arterioscler. Thromb. Vasc. Biol. 40, 1627–1634. https://doi.org/10.1161/ATVBAHA.120.312862 (2020).
doi: 10.1161/ATVBAHA.120.312862
pubmed: 32434408
pmcid: 7357605
Annex, B. H. Therapeutic angiogenesis for critical limb ischaemia. Nat. Rev. Cardiol. 10, 387–396. https://doi.org/10.1038/nrcardio.2013.70 (2013).
doi: 10.1038/nrcardio.2013.70
pubmed: 23670612
Broudy, V. C. Stem cell factor and hematopoiesis. Blood 90, 1345–1364. https://doi.org/10.1182/blood.V90.4.1345 (1997).
doi: 10.1182/blood.V90.4.1345
pubmed: 9269751
Lennartsson, J. & Ronnstrand, L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol. Rev. 92, 1619–1649. https://doi.org/10.1152/physrev.00046.2011 (2012).
doi: 10.1152/physrev.00046.2011
pubmed: 23073628
Ding, L., Saunders, T. L., Enikolopov, G. & Morrison, S. J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481, 457–462. https://doi.org/10.1038/nature10783 (2012).
doi: 10.1038/nature10783
pubmed: 22281595
pmcid: 3270376
Li, C. L. & Johnson, G. R. Stem cell factor enhances the survival but not the self-renewal of murine hematopoietic long-term repopulating cells. Blood 84, 408–414 (1994).
doi: 10.1182/blood.V84.2.408.408
pubmed: 7517713
Gardner, R. V., Oliver, P. & Astle, C. M. Stem cell factor improves the repopulating ability of primitive hematopoietic stem cells after sublethal irradiation (and, to a lesser extent) after bone marrow transplantation in mice. Stem Cells 16, 112–119. https://doi.org/10.1002/stem.160112 (1998).
doi: 10.1002/stem.160112
pubmed: 9554035
Zsebo, K. M. et al. Radioprotection of mice by recombinant rat stem cell factor. Proc. Natl. Acad. Sci. U. S. A. 89, 9464–9468. https://doi.org/10.1073/pnas.89.20.9464 (1992).
doi: 10.1073/pnas.89.20.9464
pubmed: 1384054
pmcid: 50152
Zhao, L. R., Piao, C. S., Murikinati, S. R. & Gonzalez-Toledo, M. E. The role of stem cell factor and granulocyte-colony stimulating factor in treatment of stroke. Recent Pat. CNS Drug Discov. 8, 2–12. https://doi.org/10.2174/1574889811308010002 (2013).
doi: 10.2174/1574889811308010002
pubmed: 23173646
pmcid: 3740536
Ping, S. et al. Stem cell factor and granulocyte colony-stimulating factor promote brain repair and improve cognitive function through VEGF-A in a mouse model of CADASIL. Neurobiol. of Dis. 132, 104561. https://doi.org/10.1016/j.nbd.2019.104561 (2019).
doi: 10.1016/j.nbd.2019.104561
Bath, P. M. W., Sprigg, N. & England, T. Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD005207.pub4 (2013).
doi: 10.1002/14651858.CD005207.pub4
pubmed: 23797623
Yaniz-Galende, E. et al. Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit+ cells. Circ. Res. 111, 1434–1445. https://doi.org/10.1161/CIRCRESAHA.111.263830 (2012).
doi: 10.1161/CIRCRESAHA.111.263830
pubmed: 22931954
pmcid: 3651889
Galli, S. J. et al. Reversible expansion of primate mast cell populations in vivo by stem cell factor. J. Clin. Invest. 91, 148–152. https://doi.org/10.1172/JCI116164 (1993).
doi: 10.1172/JCI116164
pubmed: 7678600
pmcid: 330008
Taylor, A. M., Galli, S. J. & Coleman, J. W. Stem-cell factor, the kit ligand, induces direct degranulation of rat peritoneal mast cells in vitro and in vivo: Dependence of the in vitro effect on period of culture and comparisons of stem-cell factor with other mast cell-activating agents. Immunology 86, 427–433 (1995).
pubmed: 8550081
pmcid: 1383947
Costa, J. J. et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J. Exp. Med. 183, 2681–2686. https://doi.org/10.1084/jem.183.6.2681 (1996).
doi: 10.1084/jem.183.6.2681
pubmed: 8676090
Da Silva, C. A., Reber, L. & Frossard, N. Stem cell factor expression, mast cells and inflammation in asthma. Fundam. Clin. Pharmacol. 20, 21–39. https://doi.org/10.1111/j.1472-8206.2005.00390.x (2006).
doi: 10.1111/j.1472-8206.2005.00390.x
pubmed: 16448392
Wershil, B. K., Tsai, M., Geissler, E. N., Zsebo, K. M. & Galli, S. J. The rat c-kit ligand, stem cell factor, induces c-kit receptor-dependent mouse mast cell activation in vivo. Evidence that signaling through the c-kit receptor can induce expression of cellular function. J. Exp. Med. 175, 245–255. https://doi.org/10.1084/jem.175.1.245 (1992).
doi: 10.1084/jem.175.1.245
pubmed: 1370530
Frangogiannis, N. G. et al. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation 98, 687–698. https://doi.org/10.1161/01.cir.98.7.687 (1998).
doi: 10.1161/01.cir.98.7.687
pubmed: 9715862
Takematsu, E. et al. Transmembrane stem cell factor protein therapeutics enhance revascularization in ischemia without mast cell activation. Nat. Commun. 13, 2497. https://doi.org/10.1038/s41467-022-30103-2 (2022).
doi: 10.1038/s41467-022-30103-2
pubmed: 35523773
pmcid: 9076913
Sligar, A. D. et al. Syndecan-4 proteoliposomes enhance revascularization in a rabbit hind limb ischemia model of peripheral ischemia. Acta Biomater. 167, 425–435. https://doi.org/10.1016/j.actbio.2023.06.006 (2023).
doi: 10.1016/j.actbio.2023.06.006
pubmed: 37321528
Sligar, A. D. et al. Preclinical model of hind limb ischemia in diabetic rabbits. J .Vis. Exp. https://doi.org/10.3791/58964 (2019).
doi: 10.3791/58964
pubmed: 31205305
Furuta, G. T., Ackerman, S. J., Lu, L., Williams, R. E. & Wershil, B. K. Stem cell factor influences mast cell mediator release in response to eosinophil-derived granule major basic protein. Blood 92, 1055–1061 (1998).
doi: 10.1182/blood.V92.3.1055
pubmed: 9680375
Feldweg, A. M. et al. gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inflammation in vivo. Eur. J. Immunol. 33, 2262–2268. https://doi.org/10.1002/eji.200323978 (2003).
doi: 10.1002/eji.200323978
pubmed: 12884301
MacNeil, A. J., Junkins, R. D., Wu, Z. & Lin, T. J. Stem cell factor induces AP-1-dependent mast cell IL-6 production via MAPK kinase 3 activity. J. Leukoc. Biol. 95, 903–915. https://doi.org/10.1189/jlb.0713401 (2014).
doi: 10.1189/jlb.0713401
pubmed: 24453276
Nam, S. Y., Kim, H. Y., Kim, H. M. & Jeong, H. J. Betaeta-eudesmol reduces stem cell factor-induced mast cell migration. Int. Immunopharmacol. 48, 1–7. https://doi.org/10.1016/j.intimp.2017.04.017 (2017).
doi: 10.1016/j.intimp.2017.04.017
pubmed: 28445842
Shpall, E. J. et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 93, 2491–2501 (1999).
pubmed: 10194427
Facon, T. et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 94, 1218–1225 (1999).
doi: 10.1182/blood.V94.4.1218
pubmed: 10438709
Maslak, P. & Nimer, S. D. The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia. Semin. Hematol. 35, 253–260 (1998).
pubmed: 9685171
Fitridge, R., Pena, G. & Mills, J. L. The patient presenting with chronic limb-threatening ischaemia. Does diabetes influence presentation, limb outcomes and survival?. Diabetes Metab. Res. Rev. https://doi.org/10.1002/dmrr.3242 (2019).
doi: 10.1002/dmrr.3242
pubmed: 31867854
Takahara, M., Iida, O., Kohsaka, S., Soga, Y., Fujihara, M., Shinke, T., Amano, T., Ikari, Y., & JEVT, investigators JP. Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: an analysis of 1,121,359 cases from the nationwide databases. Cardiovasc. Diabetol. 18, 155. https://doi.org/10.1186/s12933-019-0955-5 (2019).
Hart, D. A. Curbing inflammation in multiple sclerosis and endometriosis: Should mast cells be targeted?. Int J Inflam. 2015, 452095. https://doi.org/10.1155/2015/452095 (2015).
doi: 10.1155/2015/452095
pubmed: 26550518
pmcid: 4624887
Monument, M. J. et al. The mast cell stabilizer ketotifen fumarate lessens contracture severity and myofibroblast hyperplasia: A study of a rabbit model of posttraumatic joint contractures. J. Bone Joint. Surg. Am. 92, 1468–1477. https://doi.org/10.2106/JBJS.I.00684 (2010).
doi: 10.2106/JBJS.I.00684
pubmed: 20516323
Monument, M. J. et al. The mast cell stabilizer ketotifen reduces joint capsule fibrosis in a rabbit model of post-traumatic joint contractures. Inflamm. Res. 61, 285–292. https://doi.org/10.1007/s00011-011-0409-3 (2012).
doi: 10.1007/s00011-011-0409-3
pubmed: 22173279
Kamaruzaman, N. A., Kardia, E., Kamaldin, N., Latahir, A. Z. & Yahaya, B. H. The rabbit as a model for studying lung disease and stem cell therapy. Biomed. Res. Int. 2013, 691830. https://doi.org/10.1155/2013/691830 (2013).
doi: 10.1155/2013/691830
pubmed: 23653896
pmcid: 3638694
Ennis, M., Lorenz, W., Gerland, W. & Heise, J. Isolation of mast cells from rabbit lung and liver: comparison of histamine release induced by the hypnotics Althesin and propanidid. Agents Actions. 20, 219–222. https://doi.org/10.1007/BF02074674 (1987).
doi: 10.1007/BF02074674
pubmed: 2440276
Lanzi, C. et al. Role of histamine H(3) receptor antagonists on intraocular pressure reduction in rabbit models of transient ocular hypertension and glaucoma. Int. J. Mol. Sci. https://doi.org/10.3390/ijms20040981 (2019).
doi: 10.3390/ijms20040981
pubmed: 30813468
pmcid: 6412827
Annex, B. H. & Cooke, J. P. New directions in therapeutic angiogenesis and arteriogenesis in peripheral arterial disease. Circ. Res. 128, 1944–1957. https://doi.org/10.1161/CIRCRESAHA.121.318266 (2021).
doi: 10.1161/CIRCRESAHA.121.318266
pubmed: 34110899
pmcid: 8538391
Veith, A. P., Henderson, K., Spencer, A., Sligar, A. D. & Baker, A. B. Therapeutic strategies for enhancing angiogenesis in wound healing. Adv. Drug Deliv. Rev. 146, 97–125. https://doi.org/10.1016/j.addr.2018.09.010 (2019).
doi: 10.1016/j.addr.2018.09.010
pubmed: 30267742
Witzenbichler, B. et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 153, 381–394. https://doi.org/10.1016/S0002-9440(10)65582-4 (1998).
doi: 10.1016/S0002-9440(10)65582-4
pubmed: 9708799
pmcid: 1852989
Taniyama, Y. et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: Preclinical study for treatment of peripheral arterial disease. Gene Ther. 8, 181–189. https://doi.org/10.1038/sj.gt.3301379 (2001).
doi: 10.1038/sj.gt.3301379
pubmed: 11313789
Takeshita, S. et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem. Biophys. Res. Commun. 227, 628–635. https://doi.org/10.1006/bbrc.1996.1556 (1996).
doi: 10.1006/bbrc.1996.1556
pubmed: 8878563
Pu, L. Q. et al. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 88, 208–215. https://doi.org/10.1161/01.cir.88.1.208 (1993).
doi: 10.1161/01.cir.88.1.208
pubmed: 8319335
Morishita, R. et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 33, 1379–1384. https://doi.org/10.1161/01.hyp.33.6.1379 (1999).
doi: 10.1161/01.hyp.33.6.1379
pubmed: 10373220
Li, M. et al. Mutant hypoxia inducible factor-1alpha improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle. Microvasc. Res. 81, 26–33. https://doi.org/10.1016/j.mvr.2010.09.008 (2011).
doi: 10.1016/j.mvr.2010.09.008
pubmed: 20937289
Karatzas, A. et al. NGF promotes hemodynamic recovery in a rabbit hindlimb ischemic model through trkA- and VEGFR2-dependent pathways. J. Cardiovasc. Pharmacol. 62, 270–277. https://doi.org/10.1097/FJC.0b013e3182982de7 (2013).
doi: 10.1097/FJC.0b013e3182982de7
pubmed: 23644989
Hopkins, S. P. et al. Controlled delivery of vascular endothelial growth factor promotes neovascularization and maintains limb function in a rabbit model of ischemia. J. Vasc. Surg. 27, 886–894. https://doi.org/10.1016/s0741-5214(98)70269-1 (1998).
doi: 10.1016/s0741-5214(98)70269-1
pubmed: 9620141
Fabre, J. E., Rivard, A., Magner, M., Silver, M. & Isner, J. M. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 99, 3043–3049. https://doi.org/10.1161/01.cir.99.23.3043 (1999).
doi: 10.1161/01.cir.99.23.3043
pubmed: 10368123
Chung, Y. I. et al. Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex. J. Control Release. 143, 282–289. https://doi.org/10.1016/j.jconrel.2010.01.010 (2010).
doi: 10.1016/j.jconrel.2010.01.010
pubmed: 20093158
Nitta, N. et al. Vascular regeneration by pinpoint delivery of growth factors using a microcatheter reservoir system in a rabbit hind-limb ischemia model. Exp. Ther. Med. 4, 201–204. https://doi.org/10.3892/etm.2012.574 (2012).
doi: 10.3892/etm.2012.574
pubmed: 23139710
pmcid: 3460302
Doi, K. et al. Enhanced angiogenesis by gelatin hydrogels incorporating basic fibroblast growth factor in rabbit model of hind limb ischemia. Heart Vessels 22, 104–108. https://doi.org/10.1007/s00380-006-0934-0 (2007).
doi: 10.1007/s00380-006-0934-0
pubmed: 17390205
Wafai, R., Tudor, E. M., Angus, J. A. & Wright, C. E. Vascular effects of FGF-2 and VEGF-B in rabbits with bilateral hind limb ischemia. J. Vasc. Res. 46, 45–54. https://doi.org/10.1159/000139132 (2009).
doi: 10.1159/000139132
pubmed: 18552506
Lebherz, C. et al. Therapeutic angiogenesis/arteriogenesis in the chronic ischemic rabbit hindlimb: effect of venous basic fibroblast growth factor retroinfusion. Endothelium 10, 257–265. https://doi.org/10.1080/10623320390246432 (2003).
doi: 10.1080/10623320390246432
pubmed: 14660086
Seko, A. et al. Vascular regeneration by repeated infusions of basic fibroblast growth factor in a rabbit model of hind-limb ischemia. AJR Am. J. Roentgenol. 192, W306-310. https://doi.org/10.2214/AJR.07.4013 (2009).
doi: 10.2214/AJR.07.4013
pubmed: 19457794
Kondoh, K. et al. Conduction performance of collateral vessels induced by vascular endothelial growth factor or basic fibroblast growth factor. Cardiovasc. Res. 61, 132–142. https://doi.org/10.1016/j.cardiores.2003.10.003 (2004).
doi: 10.1016/j.cardiores.2003.10.003
pubmed: 14732210
Hosaka, A. et al. Gelatin hydrogel microspheres enable pinpoint delivery of basic fibroblast growth factor for the development of functional collateral vessels. Circulation 110, 3322–3328. https://doi.org/10.1161/01.CIR.0000147779.17602.18 (2004).
doi: 10.1161/01.CIR.0000147779.17602.18
pubmed: 15520306
Li, J. et al. Synergistic effects of FGF-2 and PDGF-BB on angiogenesis and muscle regeneration in rabbit hindlimb ischemia model. Microvasc. Res. 80, 10–17. https://doi.org/10.1016/j.mvr.2009.12.002 (2010).
doi: 10.1016/j.mvr.2009.12.002
pubmed: 20045007
Lederman, R. J. et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 359, 2053–2058. https://doi.org/10.1016/s0140-6736(02)08937-7 (2002).
doi: 10.1016/s0140-6736(02)08937-7
pubmed: 12086757
Simons, M. et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 105, 788–793. https://doi.org/10.1161/hc0802.104407 (2002).
doi: 10.1161/hc0802.104407
pubmed: 11854116
Gowdak, L. H. et al. Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 102, 565–571. https://doi.org/10.1161/01.cir.102.5.565 (2000).
doi: 10.1161/01.cir.102.5.565
pubmed: 10920070
Cao, R. et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 9, 604–613. https://doi.org/10.1038/nm848 (2003).
doi: 10.1038/nm848
pubmed: 12669032
Takeshita, S. et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest. 93, 662–670. https://doi.org/10.1172/JCI117018 (1994).
doi: 10.1172/JCI117018
pubmed: 7509344
pmcid: 293894
Chua, K. et al. Cord lining mesenchymal stem cells have a modest positive effect on angiogenesis in hindlimb ischemia. Front. Cell Dev. Biol. 8, 596170. https://doi.org/10.3389/fcell.2020.596170 (2020).
doi: 10.3389/fcell.2020.596170
pubmed: 33763413
Mikami, S. et al. Autologous bone-marrow mesenchymal stem cell implantation and endothelial function in a rabbit ischemic limb model. PLoS One. 8, e67739. https://doi.org/10.1371/journal.pone.0067739 (2013).
doi: 10.1371/journal.pone.0067739
pubmed: 23861797
pmcid: 3701528
Kim, M. S. et al. Priming with angiopoietin-1 augments the vasculogenic potential of the peripheral blood stem cells mobilized with granulocyte colony-stimulating factor through a novel Tie2/Ets-1 pathway. Circulation 120, 2240–2250. https://doi.org/10.1161/CIRCULATIONAHA.109.856815 (2009).
doi: 10.1161/CIRCULATIONAHA.109.856815
pubmed: 19917886
Fan, C. L. et al. Therapeutic neovascularization by autologous transplantation with expanded endothelial progenitor cells from peripheral blood into ischemic hind limbs. Acta Pharmacol. Sin. 26, 1069–1075. https://doi.org/10.1111/j.1745-7254.2005.00168.x (2005).
doi: 10.1111/j.1745-7254.2005.00168.x
pubmed: 16115373
Vaughan, E. E. et al. Pretreatment of endothelial progenitor cells with osteopontin enhances cell therapy for peripheral vascular disease. Cell Transpl. 21, 1095–1107. https://doi.org/10.3727/096368911X623880 (2012).
doi: 10.3727/096368911X623880
Pyun, W. B. et al. Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Ther. 17, 1442–1452. https://doi.org/10.1038/gt.2010.101 (2010).
doi: 10.1038/gt.2010.101
pubmed: 20668482
Tokunaga, N. et al. Adrenomedullin gene transfer induces therapeutic angiogenesis in a rabbit model of chronic hind limb ischemia: Benefits of a novel nonviral vector, gelatin. Circulation 109, 526–531. https://doi.org/10.1161/01.CIR.0000109700.81266.32 (2004).
doi: 10.1161/01.CIR.0000109700.81266.32
pubmed: 14732745
Vincent, K. A. et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 102, 2255–2261. https://doi.org/10.1161/01.cir.102.18.2255 (2000).
doi: 10.1161/01.cir.102.18.2255
pubmed: 11056102
Shyu, K. G., Manor, O., Magner, M., Yancopoulos, G. D. & Isner, J. M. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98, 2081–2087. https://doi.org/10.1161/01.cir.98.19.2081 (1998).
doi: 10.1161/01.cir.98.19.2081
pubmed: 9808608
Kobayashi, K. et al. Combination of in vivo angiopoietin-1 gene transfer and autologous bone marrow cell implantation for functional therapeutic angiogenesis. Arterioscler. Thromb. Vasc. Biol. 26, 1465–1472. https://doi.org/10.1161/01.ATV.0000223865.64812.26 (2006).
doi: 10.1161/01.ATV.0000223865.64812.26
pubmed: 16645159
Pinkenburg, O. et al. Recombinant adeno-associated virus-based gene transfer of cathelicidin induces therapeutic neovascularization preferentially via potent collateral growth. Hum Gene Ther. 20, 159–167. https://doi.org/10.1089/hum.2007.178 (2009).
doi: 10.1089/hum.2007.178
pubmed: 20377367
Chen, F., Tan, Z., Dong, C. Y., Chen, X. & Guo, S. F. Adeno-associated virus vectors simultaneously encoding VEGF and angiopoietin-1 enhances neovascularization in ischemic rabbit hind-limbs. Acta Pharmacol. Sin. 28, 493–502. https://doi.org/10.1111/j.1745-7254.2007.00527.x (2007).
doi: 10.1111/j.1745-7254.2007.00527.x
pubmed: 17376288
Zhang, C. et al. Angiopoiesis and bone regeneration via co-expression of the hVEGF and hBMP genes from an adeno-associated viral vector in vitro and in vivo. Acta Pharmacol. Sin. 31, 821–830. https://doi.org/10.1038/aps.2010.67 (2010).
doi: 10.1038/aps.2010.67
pubmed: 20581855
pmcid: 4007728
Dai, Q. et al. Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 110, 2467–2475. https://doi.org/10.1161/01.CIR.0000145139.53840.49 (2004).
doi: 10.1161/01.CIR.0000145139.53840.49
pubmed: 15477407
Jiang, H., Zhang, T. & Sun, X. Vascular endothelial growth factor gene delivery by magnetic DNA nanospheres ameliorates limb ischemia in rabbits. J. Surg. Res. 126, 48–54. https://doi.org/10.1016/j.jss.2005.01.005 (2005).
doi: 10.1016/j.jss.2005.01.005
pubmed: 15916974
Cui, K. et al. Dual gene transfer of bFGF and PDGF in a single plasmid for the treatment of myocardial infarction. Exp. Ther. Med. 7, 691–696. https://doi.org/10.3892/etm.2014.1485 (2014).
doi: 10.3892/etm.2014.1485
pubmed: 24520269
pmcid: 3919859
Ohara, N. et al. Adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor promotes collateral development in a rabbit model of hind limb ischemia. Gene Ther. 8, 837–845. https://doi.org/10.1038/sj.gt.3301475 (2001).
doi: 10.1038/sj.gt.3301475
pubmed: 11423931
Nishikage, S. et al. In vivo electroporation enhances plasmid-based gene transfer of basic fibroblast growth factor for the treatment of ischemic limb. J. Surg. Res. 120, 37–46. https://doi.org/10.1016/j.jss.2003.12.016 (2004).
doi: 10.1016/j.jss.2003.12.016
pubmed: 15172188